Share

April 21, 2015; 84 (16) Article

Acute infarcts cause focal thinning in remote cortex via degeneration of connecting fiber tracts

Marco Duering, Ruthger Righart, Frank Arne Wollenweber, Vera Zietemann, Benno Gesierich, Martin Dichgans
First published March 25, 2015, DOI: https://doi.org/10.1212/WNL.0000000000001502
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
508

Share

Article Information

vol. 84 no. 16 1685-1692
DOI: 
https://doi.org/10.1212/WNL.0000000000001502
PubMed: 
25809303
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received October 15, 2014
  • Accepted in final form January 14, 2015
  • First Published March 25, 2015.

Article Versions

Copyright & Usage: 
© 2015 American Academy of Neurology

Author Disclosures

    1. Marco Duering, MD*,
    2. Ruthger Righart, PhD*,
    3. Frank Arne Wollenweber, MD,
    4. Vera Zietemann, PhD,
    5. Benno Gesierich, PhD and
    6. Martin Dichgans, MD
  1. Marco Duering, MD*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. travel expenses for lectures from the United Leukodystrophy Foundation, the European Stroke Conference and Kenes International.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) German Center for Neurodegenerative Diseases (DZNE), VaD/MixD, PI, 2011-2014

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Vascular Dementia Research Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ruthger Righart, PhD*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Frank Arne Wollenweber, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Vera Zietemann, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Benno Gesierich, PhD and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Martin Dichgans, MD
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Bayer Vital, travel expenses and honoraria for lectures, (2) Boehringer Ingelheim Pharma, travel expenses and honoraria for lectures, (3) Heel, travel expenses and honoraria for lectures, (4) Bristol-Meyer Squibb, travel expenses and honoraria for lectures, (5) Lundeck, travel expenses and honoraria for lectures, (6) Sanofi- Aventis, travel expenses and honoraria for lectures, (7) Shire, travel expenses and honoraria for lectures, (8) German Research Foundation (DFG), research support, (9) Vascular Dementia Research Foundation, research support, (10) Corona Foundation, research support, (11) Jackst?dt Foundation, research support.

    Editorial Boards:

    1. (1) Stroke the International Journal of Stroke, editor, (2) Cerebrovascular diseases, editorial board member, (3) Journal of Neurochemistry, editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Bayer Vital, (2) Boehringer Ingelheim, (3) Bristol-Meyer Squibb, (4) Heel

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) Wellcometrust, 03/08 following, (2) European Union (EU FP 7), investigator, 10/13-09/16, (3) German Federal Ministry of Education and Research (BMBF), investigator, 12/13-11/16, (4) European Union (EU FP 6), investigator, 03/12-02/15

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Vascular Dementia Research Foundation, (2) Corona Foundation, (3) Jackst?dt Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Institute for Stroke and Dementia Research (M.D., R.R., F.A.W., V.Z., B.G., M.D.), Klinikum der Universität München, Ludwig-Maximilians University, Munich; German Center for Neurodegenerative Diseases (DZNE, Munich) (R.R., M.D.), Munich; and Munich Cluster for Systems Neurology (SyNergy) (M.D.), Munich, Germany. R.R. is currently with the Department of Neurology, Technische Universität München, Munich, Germany.
  1. Correspondence to Dr. Dichgans: martin.dichgans{at}med.uni-muenchen.de
View Full Text

Article usage

Article usage: March 2015 to December 2019

AbstractFullPdfSource
Mar 2015276023Highwire
Apr 201512741360Highwire
May 20153361119Highwire
Jun 2015149611Highwire
Jul 201512179Highwire
Aug 201513698Highwire
Sep 20157628Highwire
Oct 20154485Highwire
Oct 2015072pmc
Nov 20155085Highwire
Nov 201502114pmc
Dec 20154322Highwire
Dec 201501510pmc
Jan 20164112Highwire
Jan 20160139pmc
Feb 20164514Highwire
Feb 20160168pmc
Mar 20162822Highwire
Mar 20160810pmc
Apr 20164265Highwire
Apr 20160136pmc
May 20163214Highwire
May 2016067pmc
Jun 20163522Highwire
Jun 2016061pmc
Jul 20162046Highwire
Jul 2016072pmc
Aug 20163211Highwire
Aug 20160118pmc
Sep 20163821Highwire
Sep 201601212pmc
Oct 20162934Highwire
Oct 20160147pmc
Nov 20163022Highwire
Nov 20160104pmc
Dec 20163122Highwire
Dec 201601510pmc
Jan 20173432Highwire
Jan 201702614pmc
Feb 20173111Highwire
Feb 20170118pmc
Mar 20172813Highwire
Mar 20170156pmc
Apr 20172811Highwire
Apr 201741415pmc
May 20171810Highwire
May 2017588pmc
Jun 20171912Highwire
Jun 2017156pmc
Jul 20171900Highwire
Jul 201751312pmc
Aug 20172501Highwire
Aug 201771316pmc
Sep 20171400Highwire
Sep 2017078pmc
Oct 20172000Highwire
Oct 201761716pmc
Nov 20172411Highwire
Nov 2017377pmc
Dec 20172912Highwire
Jan 20181311Highwire
Feb 20181500Highwire
Mar 20181520Highwire
Apr 20182431Highwire
Apr 201871522pmc
May 20181732Highwire
Jun 20181611Highwire
Jun 201861918pmc
Jul 20183100Highwire
Aug 20181300Highwire
Aug 201822019pmc
Sep 20181000Highwire
Oct 20182400Highwire
Nov 20181310Highwire
Dec 20183311Highwire
Jan 20191144Highwire
Feb 20192920Highwire
Mar 20192043Highwire
Apr 2019700Highwire
May 20192731Highwire
Jun 20192111Highwire
Jul 20191701Highwire
Aug 20192711Highwire
Sep 20191121Highwire
Oct 20191701Highwire
Nov 20194035Highwire
Dec 20191601Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me